Evaluation of the Novel XF Drugs as Bacterial Resistance Breakers

There is an urgent need for new drugs to treat infections resulting from bacteria that are now resistant to many of the current marketed antibiotics. This is a global issue encountered in low and middle-income countries (LMICs) where healthcare provisions may be less prevalent and so the impact is even greater.

The jointly funded UK Department of Health and Social Care (DHSC) and Chinese Ministry of Science and Technology

(MoST) Anti-Microbial Resistance (AMR) Industrial Research program aims to extend the knowledge surrounding the efficacy of novel anti-bacterial XF drugs to tackle World Health Organisation (WHO)-identified, high priority, multi-drug resistant (MDR) bacterial pathogens.

The program will also examine the efficacy of these novel drugs in combination with existing, but largely ineffective antibiotics. Positive data from this study could lead to the development of a range of new medicines that could be competitively priced so as to permit patients from LMICs and China greater access to affordable medication.